Skip to main content
Equibles

Caligan Partners LP

Position in MBX — MBX Biosciences, Inc.

CIK 1727492 NEW YORK, NY
Back to MBX Full portfolio

Position in MBX

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$11,040,000
-$14,290,411 QoQ
Shares Held
200,000
-76.4% QoQ
Ownership
0.415%
of shares outstanding
% of Portfolio
0.53%
of 13F equity value
Holder Rank
#43
of 172 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in MBX Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Caligan Partners LP holds $1,404,383,722 across 23 Biotechnology names. MBX ranks #21 (0.8% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 RVMD
Revolution Medicines, Inc.
 1,961,795 $367,404,967
2 ABVX
Abivax S.A.
 1,557,924 $207,608,952
3 PCVX
Vaxcyte, Inc.
 2,188,636 $127,225,410
4 EXEL
Exelixis, Inc.
 1,553,262 $84,512,985
5 TNGX
Tango Therapeutics, Inc.
 2,500,103 $78,153,219
6 AVTX
Avalo Therapeutics, Inc.
 3,163,866 $58,468,243
7 XENE
Xenon Pharmaceuticals Inc.
 889,944 $53,717,019
8 ADMA
Adma Biologics, Inc.
 5,725,007 $47,918,308

All Filings in MBX

Export CSV
2 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $11,040,000 200,000
2026-03-31 $25,330,411 848,590